The Orange Book vs. Purple Book Playbook: Why Biosimilar Development Costs 100x More Than Generic
The gap between developing a generic drug and a biosimilar is not regulatory paperwork. It is the difference between a […]
The Generic Drug Playbook: Patent Cliffs, ANDA Strategy, and the $400B Race to Market
Why the Patent Cliff Is the Pharmaceutical Industry’s Most Predictable Crisis — and the Generic Industry’s Biggest Opportunity Every dollar
The Generic Drug Playbook: Patent Cliffs, ANDA Strategy, and the $400B Race to Market Read Post »
How Pharma Patent Litigation Data Predicts Generic Entry, Settlement Terms, and Revenue Risk
When Paragraph IV filings hit the docket, they set off a chain of financial events most analysts only half-understand. Here
The $200B Secondary Patent Playbook: How Pharma Defends Drug Revenue After the Compound Patent Expires
Every pharmaceutical analyst knows when the compound patent expires. It is on the Bloomberg terminal, in the 10-K, in every
The Patent Playbook: 7 Key Strategies Pharma Uses to Extend Market Exclusivity
The average branded drug reaches pharmacy shelves with roughly 10 to 12 years of effective patent life remaining. The average
The Patent Playbook: 7 Key Strategies Pharma Uses to Extend Market Exclusivity Read Post »
Pharma White Space Analysis: The R&D Intelligence Playbook That Separates First Movers from Followers
The $200 billion patent cliff bearing down on Big Pharma through 2030 is not primarily a manufacturing or regulatory problem.
Generic Drug Reverse Engineering: The Complete IP, Regulatory, and Deformulation Playbook
The patent cliff is not a metaphor. When Humira’s U.S. composition-of-matter patent finally cracked open in 2023, AbbVie had already
PTAB Risk, Decoded: When a Drug Patent Is Truly Secure (and When It Isn’t)
A single composition-of-matter patent can represent $40 billion in franchise value. At the Patent Trial and Appeal Board (PTAB), that
PTAB Risk, Decoded: When a Drug Patent Is Truly Secure (and When It Isn’t) Read Post »
Paragraph IV Dispute Resolution: The Complete Playbook for Pharma IP Teams and Portfolio Managers
A Paragraph IV filing is not a legal emergency. It is a predictable business event built into the architecture of
